The effects of endogenous cortisol on binucleate cells (BNCs), which promote fetal growth, may be mediated by glucocorticoid receptors (GRs), and exposure to dexamethasone (DEX) in early pregnancy stages of placental development might modify this response. In this article, we have investigated the expression of GR as a determinant of these responses. Pregnant ewes carrying singleton fetuses (n ¼ 119) were randomized to control (2 mL saline/ewe) or DEX-treated groups (intramuscular injections of 0.14 mg/kg ewe weight per 12 hours) at 40 to 41 days of gestation (dG). Placental tissue was collected at 50, 100, 125, and 140 dG. Total glucocorticoid receptor protein (GRt) was increased significantly by DEX at 50 and 125 dG in females only, but decreased in males at 125 dG as compared to controls. Glucocorticoid receptor a (GRa) protein was not changed after DEX treatment. Three BNC phenotypes were detected regarding GRa expression (þþ, þÀ, ÀÀ), DEX increased the proportion of (þþ) and decreased (ÀÀ) BNC at 140 dG. Effects were sex-and cell type dependent, modifying the responsiveness of the placenta to endogenous cortisol. We speculate that 3 maturational stages of BNCs exist and that the overall activity of BNCs is determined by the distribution of these 3 cell types, which may become altered through early pregnancy exposure to elevated glucocorticoids.
Introduction
In women at risk of early preterm birth, maternal synthetic glucocorticoid (GC) administration is an important clinical tool to reduce neonatal mortality and morbidity from respiratory distress syndrome. [1] [2] [3] In early pregnancy, antenatal GCs are used in suspected cases of congenital adrenal hyperplasia (CAH) to prevent female fetuses from virilization. 4, 5 Although the long-term effects of prenatal GC exposure late in pregnancy are well documented in experimental studies, little is known about the mechanisms that regulate outcomes of early exposure. We have previously shown in sheep that early dexamethasone (DEX) treatment resulted in sex-specific altered fetal and organ weights and function, some of which persisted into later life. [6] [7] [8] The placenta, as the conduit between the maternal and fetal environment, and its development and function may play a role in mediating fetal GC exposure, administered early in pregnancy on key phases of placental development. 9, 10 Exogenous doses of maternal GCs in pregnancy are associated with sexspecific, fetal growth restriction, and structural and functional changes in the placenta, which potentially can have life-long impact on health of the affected individual. 11 Sex-specific strategies for adapting to a changed environment in utero have been described in both animal and human studies. [12] [13] [14] [15] [16] [17] [18] [19] [20] In our animal studies, pregnant sheep were administered an amount of DEX analogous to that used in humans in the one-third of pregnancy but given as a 2-day bolus, in contrast to continuous clinical treatment with GC over weeks as in cases of CAH. We have shown that early maternal DEX therapy, as a model for both CAH treatment and early maternal distress, did not lead to growth restriction in male fetuses, whereas in female fetuses DEX treatment resulted in a transient growth reduction which was associated with significantly lower binucleate cell (BNC) numbers and increased apoptotic markers, but was not reflected in changes in ovine placental lactogen (oPL) protein levels. 21 The underlying mechanisms remain to be elucidated and the purpose of this study is to evaluate the presence of GR as an essential intermediate in regulating BNC function and placental development with respect to DEX treatment in early pregnancy.
In the sheep placenta, about 15% to 20% of the total fetal trophoblast cell number consists of BNCs. These contain granules of oPL which promote fetal growth. 22 Early DEX treatment at 40 to 41 days of gestation (dG) in females resulted in reduced BNC numbers, reduced placental anti-proliferating cell nuclear antigen, and increased proapoptotic factors (Bax, p53), associated with a temporary decrease in fetal growth. 21 However, neither placental oPL protein nor fetal or maternal plasma levels were changed at 100 dG. The regulatory factors associated with this apparent paradox at 100 dG, suggestive of increased BNC output of oPL to maintain placental and plasma concentrations, remain unclear.
Glucocorticoid effects on intrauterine tissues are mediated in part by glucocorticoid receptors (GRs). 23 In humans, the GR (often referred to as the total GR [GRt]) has 2 major isoforms, namely GRa (777 amino acids) and GRb (742 amino acids) which share 1 to 727 amino acids and differ in their carboxy-terminal sequences as well as molecular weights. [24] [25] [26] The ligand-dependent GRa stimulates GC target gene transcription and is hypothesized to be the active receptor isoform. 25 GRb is ligand independent and acts as a dominant negative regulator of GRa, 26 although conflicting evidence exists. [27] [28] [29] In sheep, during the onset and progression of spontaneous labor, temporal and tissue-specific patterns of GR expression within intrauterine tissues have been described earlier. 30 GRt, GRa, and GRb proteins have been localized to trophoblast cells of the placenta, fetal amnion, chorion, and in maternal endometrium. 30 The localization did not change during labor progression, the protein levels of GRt, as well as GRa increased in placental tissues during labor, suggesting the possibility of increased responsiveness to cortisol at the onset and during progression of labor. 30 Glucocorticoid treatment significantly affected BNC numbers and function 21, 31 ; however, it is not clear whether the responses in BNCs are due to the exogenous GC treatment or due to changes in the endogenous cortisol levels or due to an interaction between them at the GR level, for example, due to a DEX-induced downregulation of GR, which makes the tissue less responsive to endogenous cortisol. Therefore, the aim of this study was to investigate the effects of endogenous plasma cortisol and exogenous early maternal DEX in sheep on GR.
We investigated the effects of early DEX treatment in sheep on GR localization and distribution and measured GR protein levels in placentomes. Colocalization studies of GRa-stained BNCs with oPL as a marker for BNC function and caspase 3 as a marker for apoptotic degradation were performed to investigate GR-related BNC function. Based on our previous studies, we hypothesized that effects would be sex-specific and placentome subtype dependent. 21, [32] [33] [34] 
Materials and Methods
All experimental procedures were approved by the Animal Experimentation Ethics Committee of the University of Western Australia and/or the Western Australian Department of Agriculture. Pregnant Merino ewes (Ovis aries) with singleton pregnancies of known gestational age were randomized to control-(n ¼ 59, 2 mL saline/ewe) or DEX-treated groups (n ¼ 49, intramuscular injections of 0.14 mg/kg ewe weight per 12 hours over 48 hours, in total 4 injections) at 40 to 41 dG. Hysterectomy was performed at 49 to 51 (50), 101 to 103 (100), 125 to 127 (125), and 140 to 142 (140) dG, and placentomes were dissected from the uterus. 31, 34 Placentomes were bisected and halves were either snap frozen in liquid nitrogen before storage at À80 C or fixed in 4% paraformaldehyde for 24 hours (Sigma Chemical Co., St. Louis, Missouri) according to standard procedures for future embedding in paraffin prior to sectioning. The placentomes that have been identified according to gross morphological appearance (4 types: A, B, C, and D), reflecting the degree of eversion of the hemophagous zone. 35 Maternal (jugular) and fetal (cardiac at 50 dG or umbilical arterial) blood samples and other major fetal organs were collected for use in other studies. [6] [7] [8] 21 Localization of GRt, GRa, GRb, and Caspase 3 GRt, GRa and GRb. Immunohistochemical staining of GR isoforms were performed on saggital cross-sections (6 mm) in the middle of the placentomes. 31 The specificity for GRt and GRa has been previously demonstrated 30, 36 and was confirmed in this study with Western blotting ( Figure S1 ). Briefly, incubation with monoclonal mouse antirat GRt at 1:50 (MA1-510, Thermo Scientific, Utah), 36 polyclonal rabbit antihuman GRa at 1:100 (P-20:sc1002, Santa Cruz), 30 or polyclonal rabbit antihuman GRb at 1:100 (PA3-514, Thermo Scientific) 30, 37 diluted in 2% normal goat serum was performed in a humidity chamber at 4 C overnight. Tissue sections were incubated with biotinylated antirabbit immunoglobulin G (IgG) antibody (PK-4001 Vectastain ABC kit, Vector Laboratories) at 1:200 and treated with ABC solution for 60 minutes (PK-4001 Vectastain ABC kit, Vector Laboratories California). Slides were exposed to 3 0 ,3-diaminobenzidine tetrahydrochloride (DAB, Roth Chemical Kansas) as a chromogen for 10 minutes. Tissue sections from each group were processed in 1 assay to allow direct comparison between experiments. Three sets of negative controls were included as follows: (1) the primary antibody was substituted by nonimmune rabbit serum (1:200 dilution); (2) the peroxidase-labeled secondary link antibody (goat antirabbit and donkey antirabbit immunoglobulin) was substituted with nonimmune goat/horse serum (1:200 dilution); and (3) the slide section was only incubated with nonimmune goat/horse serum (1:200 dilution) before the addition of the substrate-chromogen solution.
Caspase 3. Sections were incubated with polyclonal rabbit antihuman active caspase 3 at 1:1000 (AF835, R&D Systems, Australia) 38 and with biotinylated antirabbit IgG antibody at 1:200 (cat. no. 711-066-152, Jackson ImmunoResearch Europe Ltd., United Kingdom). Sections were labeled with streptavidin-alkaline phosphatase and the red precipitate was developed with Fast red (cat. no. K5005, Dako Real Detection System, Denmark).
Colocalization of GRa, oPL, and Caspase 3
Double staining of GRa and oPL. The GRa staining with DAB was performed in the first step, then the sections were washed in Tris-HCL (pH 7.5, Carl Roht GmbH and Merck AG, Germany) buffered for 5 minutes and 3 Â 5 minutes in phosphatebuffered saline (PBS) before incubated with a rabbit anti-oPL at 1:20 000 and Fast red (ab64254, Abcam, UK) was used as chromogen for oPL.
Double staining of GRa and caspase 3. GRa staining with DAB was performed in the first step, then the sections were washed in Tris-HCL (pH 7.5, Carl Roht GmbH and Merck AG, Germany) buffered for 5 minutes and 3 Â 5 minutes in PBS and 0.15% Tween-20 (Sigma Chemical Co.), followed by Caspase-3 staining with Fast red as described previously.
Image Analyses
Semiquantitative analyses were performed using computerized image analysis (ImageJ 1.43u, National Institutes of Health, USA). To reduce the number of false positive counts, GRa BNCs were counted only if >30% of the cytoplasm of a BNC was visible and at least 80% of the randomly selected field of view was covered with placental tissue. 31 A total of 18 random fields of view were counted in each section of immunostained tissue at a magnification of 20Â. At least 2 sections per placentome (n ¼ 191 from 97 sheep) were counted, over 6500 fields of view were analyzed by 1 person blinded to the treatment protocol. The mean number of BNCs was expressed per 1500 mm 2 + standard error of the mean (SEM).
Quantification of GRt, GRa, and GRb Protein Levels: Western Blotting
Quantification of protein levels with Western blotting was performed as described previously. 31 Each gel contained samples of different treatment groups, sex, placentome subtypes, and gestational age to facilitate comparison between all factors and was repeated at least 3 times. Membranes were incubated overnight with the same primary antibodies used for immunohistochemistry, but at a dilution of 1:1000 for GRt, 1:200 for GRa, and 1:200 for GRb. The antibody-antigen complex was detected using a chemiluminescence detection system (34075, ECL, Thermo Scientific). Membranes were incubated without primary antibody or with primary antibody, preabsorbed with specific binding peptides (GRa blocking peptide: sc-1002 P, Thermo Scientific, GRb blocking peptide: PEP-222, Thermo Scientific). Since there is no GRt blocking peptide for this commercially available specific antibody, the protein sequence of the GRt 97-kDa band was analyzed by Proteome Factory (Berlin, Germany) and the antibody specificity for GRt (GenBank:EU371026.1) was given. All blots were reincubated with anti-b-actin at 1:20 000 (107K4800, Sigma) as an internal control to allow correction for gel loading and transfer. Band density for both the protein of interest and b-actin was quantified by densitometry (Quantity One 4.6.2, Bio-Rad, California). Results were expressed as the ratio of protein to b-actin as relative optical density.
Statistical Analysis
Analyses were performed by using SPSS 20 statistical software (SPSS Inc, Chicago). Data were tested for normal distribution and equal variance (Levene test, P > .05). Data that were not normally distributed were log transformed to achieve normality. GRa BNC numbers/mean percentages: To determine dG, treatment, GRa subtypes (þþ, þÀ, ÀÀ), placentome subtype, and gender effects as well an interaction between them on GRa BNC numbers, data sets were analyzed using a full factorial model (multivariate analysis of variance [MANOVA]) with dG, treatment, GRa subtype (þþ, þÀ, ÀÀ), placentome subtype, and gender as factors. GR protein levels: To determine dG, treatment, placentome subtype, and gender effects as well an interaction between them on GR protein levels, data sets were analyzed using an MANOVA with dG, treatment, placentome subtype, and gender as factors. The MANOVA tests were followed by a pairwise comparison (Holm-Sidak) when main effects were P < .05. Main effects and interactions are indicated in the Result section as well as in Figure 1 where significant (P < .05), post hoc P-values (Holm-Sidak) are indicated. The relationship between the mean number of GRa stained BNCs with previously reported placental oPL protein and maternal and fetal oPL plasma levels 21 and maternal and fetal cortisol plasma levels 6 of the same cohort of animals ( 
Results

Localization and Distribution of GR
As described previously, GRt and GRa were localized in the cytosol and nucleus of the trophoblast cells throughout the placentome and in fetal membranes 30, 36 and GR presence was independent of gestational age, fetal sex, placentome subtype, and treatment. No specific GRb staining was detectable. GRa staining was also present within BNC, with 3 different nuclear staining patterns observed: BNCs with 2 GRa positive stained nuclei (þþ), BNCs lacking any GRa staining in the nuclei (ÀÀ), and BNCs with 1 positive and 1 negative stained GRa nucleus (þÀ; Figure 1A and B). These nuclear staining patterns were found in both males and females, control-and DEX-treated placentomes, and were independent of placentome subtype and gestational age.
Irrespective of BNC types, placentome subtype or gender, mean number of GRa BNCs in controls did not change across gestation (P > .05, Figure 2A ). In all fetuses, (þþ) BNC was the most frequent cell type and (ÀÀ) the least frequent cell type (MANOVA main effects: dG P < .05, treatment P < .05, and GRa-type P < .05; placentome subtype P < .05; interaction: dG Â treatment P < .05, dG Â GRa-type P < .05, dG Â placentome subtype P < .05). The mean number and proportion of (þþ) GRa BNCs in controls significantly increased from 50 to 100 dG and decreased thereafter from 100 to 140 dG (P < .05; Figure 2B ). The proportion of total of (þÀ) and (ÀÀ) decreased from 50 to 100 dG and thereafter increased between 100 and 140 dG (P < .05, Figure 2B ).
The Effect of DEX on GRa Localization and Distribution
Early DEX treatment significantly reduced the mean number of (þþ) GRa BNCs at 100 dG and the mean number of all 3 GRa BNC types at 140 dG (Figure 2A) . In contrast to controls, the proportion of all 3 nuclear GRa BNC staining patterns did not change between 100 and 140 dG, therefore resulting in significant lower proportion of (ÀÀ) GRa BNCs and significant higher proportion of (þþ) GRa BNCs at 140 dG as compared to controls (MANOVA main effects: dG P < .05, treatment P < .05, GRa-type P < .05; interactions: dG Â GRa-type P < .05, P < .05; dG Â treatment P < .05; Figure 2B ).
Placental GR Protein Levels and the Effect of DEX
GRt protein was detected as a single 97-kDa band as described previously 39 and the detected band was proven to be specific for GRt by protein sequencing (GenBank: EU371026.1). In control males, GRt protein levels were highest at 125 dG and decreased toward term (MANOVA main effects: dG P < .05; interaction: treatment Â type P < .05; dG Â treatment Â sex P < .05; Figure 3A ). In control females, no significant changes in GRt protein levels across gestation were observed. Dexamethasone significantly increased GRt protein level in females at 50 dG and at 125 dG compared to controls ( Figure 3A ). This decrease was significant for A-subtypes at 50 dG and for Bsubtypes at 125 dG (P < .05). In males, however, GRt protein levels were significantly decreased at 125 dG compared to controls ( Figure 3A) , predominantly in C-and D subtypes.
GRa protein was identified at 95-kDa as described previously 30, 36 and its specificity was proven with a blocking peptide ( Figure S1A ). In both males and females, lowest GRa protein levels were found at 140 dG (MANOVA main effects: dG P < .05; interaction: P > .05; Figure 3B ). Dexamethasone did not affect GRa protein level (P > .05, Figure 3B ). No differences in GRa protein levels were found regarding placentome subtypes.
The band found at 97-kDA which was described as GRb previously 30 could not be blocked with the specific blocking peptide that is currently commercially available ( Figure S1B ).
The relationship between GRt (protein) and GRa (BNC numbers and protein) with placental oPL protein and maternal and fetal oPL, cortisol, and adrenocorticotropic hormone (ACTH) plasma levels is explained subsequently:
In control females, GRa BNC numbers (þþ) were negatively correlated with previously reported fetal cortisol 6 plasma levels (r ¼ À.446, P < .01) and were positively correlated with previously reported oPL protein 21 levels (r ¼ .592, P < .01, Table S1 ). After DEX treatment, (þþ) GRa BNC types were independent of fetal cortisol plasma levels, but the (þÀ) GRa BNC became positively correlated with oPL protein and maternal oPL plasma levels (P < .05). The GRt protein levels lost their positive correlation with oPL protein levels after DEX, whereas GRa protein levels became positively correlated with oPL protein levels (r ¼ .481, P < .05) after DEX treatment. Both GRt and GRa protein levels did not significantly correlate with maternal or fetal cortisol and ACTH plasma levels.
In males, GRa BNCs numbers of all types were positively correlated with oPL protein levels (P < .05). After DEX treatment, this was not seen anymore for (þÀ) and (ÀÀ) GRa BNCs (Table S1 ). GRa BNCs and protein levels were independent of maternal or fetal cortisol levels (P > .05), but after DEX treatment, GRa protein levels were inversely correlated with fetal cortisol levels (r ¼ À.487, P < .05). GRt protein levels in both controls and DEX were independent of maternal or fetal cortisol and ACTH plasma levels. 
Maturational Differences in BNCs: GRa Double Staining With oPL or Caspase 3
Ovine placental lactogen localized predominately to the cytoplasm of the BNCs, with little immunostaining in the maternal syncytium as reported previously ( Figure 1D ). 31, 39 Double staining of BNCs for GRa and oPL showed 3 different staining patterns: BNCs with oPL positive stained cytoplasm and 2 GRa positive stained nuclei (þþ); BNCs with oPL positive stained cytoplasm and 1 positive and 1 negative GRa stained nucleus (þÀ); and BNCs without oPL positive stained cytoplasm and no GRa-stained nucleus (ÀÀ) (Figures 1E and 4) . Caspase 3 localized predominately to the nuclei of BNCs, with little immunostaining in the maternal syncytium, fetal, and maternal stroma. Binucleate cells with 2 caspase-3 positive stained nuclei, BNCs lacking any caspase-3 staining in the nuclei, and BNCs with 1 positive and 1 negative caspase-3 stained nucleus were found (Figures 1 [F 
Discussion
Dexamethasone treatment in early pregnancy is associated with transient sex-specific alterations in placental development and function and fetal growth. Placental GRt protein levels were increased significantly by DEX in females at 50 and 125 dG, but decreased in males at 125 dG as compared to controls. GRa protein levels were not changed after DEX treatment. Three BNC phenotypes were detected regarding GRa expression (þþ, þÀ, and ÀÀ); DEX increased the proportion of (þþ) and decreased (ÀÀ) BNC at 140 dG. Effects were sex-and cell type dependent suggesting a modified responsiveness of the placenta to endogenous cortisol.
In this study, we were able to analyze GRt and GRa protein levels from early pregnancy, at 50 dG, up to 140 dG for both females and males separately. In females, GRt protein levels did not change significantly across gestation, whereas in males, highest levels of GRt protein levels were found at 125 dG, and then decreased toward 140 dG. Placental GRa protein levels were lowest at 140 dG in both females and males, suggesting a reduced placental responsiveness to near-term cortisol. Previous studies on direct cortisol infusion to the fetus resulted in increased GRa but not GRt protein levels in sheep placenta. 30 In females, early DEX significantly increased GRt protein levels at 50 and 125 dG, in males, however, DEX significantly decreased GRt protein levels at 125 dG compared to controls. Although in female fetuses a constant placental GC sensitivity is maintained, possibly in terms of a preferential survival strategy for ensuring reproductive capacity and species conservation, it seems that in male fetuses due to increased GC exposure, the placenta becomes at least temporarily GC resistant. In both females and males, GRa protein levels were not affected by early DEX, but in males became significantly correlated with oPL protein and fetal cortisol levels after DEX treatment, indicating a greater importance of GRa for cortisol responsiveness and oPL production and secretion.
As described and discussed previously by Root et al 37 who used the same GRb antibody as described by Gupta et al, 30 we were also not able to find a specific band for GRb. The band found at 97-kDA was very weak and could not be blocked with the specific blocking peptide that is now commercially Figure 2 . A, Mean number (A) and percentage (B) of GRa positive stained BNCs in control and DEX groups. A, Presenting the total number of GRa positive binucleate cells at each age, and the effect of dexamethasone, irrespective of placentome subtypes, sex, and BNC types. DEX treatment significantly reduced the mean number of GR positive stained BNCs at 140 dG*, which was significant for all 3 BNC subtypes (þþ, þÀ, ÀÀ, see Result section). Small letters (a) indicate no significant differences in control groups across gestation. Differences in capital letters indicate significant differences in the DEX groups across gestation. B, Presenting the mean percentage of total GRa positive stained BNCs at each age, and the effect of dexamethasone, irrespective of placentome subtypes and sex. Different numbers indicate significant differences across gestation per cell type. Significant differences between control and DEX per cell type are indicated with stars. The number of sheep included in the study are given subsequently (n ¼ control/DEX). Significant difference was accepted for P < .05. DEX: indicates dexamethasone; BNCs, binucleate cells; GR, glucocorticoid receptors; dG, days of gestation.
available ( Figure S1B ). It was suggested that the expression of GRb is either very low in sheep placenta or the previously reported GRb antibody, whose specificity can now be tested with a blocking peptide, revealed a non-specific binding of GRb. 37 In a very recent study, Saif et al identified 12 isoforms of the GR in the human placenta, which were localized to the trophoblast cells and expression varied in relation to cellular location in either the cytoplasm or nucleus, fetal sex, fetal size, but not all isoforms were expressed in every individual. 40 Therefore, we would like to suggest that other GR isoforms may also be present in the sheep placenta, which could contribute to the changes observed in GRt protein but not GRa protein, but this has to be elucidated in the future.
Evidence for differences in protein expression being affected by anatomical localization of BNCs has been reported previously. 41 Now, for the first time in this study, 3 different immunostaining patterns of GRa in BNCs have been observed.
However, the separate function of these BNC types, if present, still remains unclear. We hypothesized based on our current and previous observations that the most frequently observed staining pattern, with 2 GRa positive stained nuclei (þþ), is a potential ''active'' BNC form, whereas the least frequently observed staining pattern, lacking GRa nuclear staining (ÀÀ), is an ''immature'' or ''inactive'' BNC form (Figure 4 ). Since BNCs produce oPL, colocalization of GRa and oPL was used to determine whether a (þþ) GRa BNC would contain oPL granules in the cytoplasm. Indeed, (þþ) GRa BNCs stained positively for oPL in the cytoplasm, whereas the (ÀÀ) GRa BNCs did not have positive oPL staining in the cytoplasm. A third GRa staining pattern in BNCs was also found, in which only 1 nucleus was positively stained for GRa, the other nucleus was lacking GRa staining (þÀ). Colocalization of GRa and oPL showed oPL positive cytoplasm in this third staining pattern and we speculate that this cell type may be an ''intermediate'' BNC form. It has been shown previously by others [42] [43] [44] and also in our own DEX treatment model 21 that GC treatment can be associated with increased rates of apoptosis. Consistent with this, colocalization of GRa with active caspase 3 revealed strong nuclear caspase-3 staining in the (ÀÀ) GRa BNC to support this GRa BNC type being ''inactive,'' whereas in the (þþ) GRa BNC form, no caspase-3 nuclear staining was observed. We hypothesize, that 2 maturational forms of ''intermediate'' (þÀ) GRa BNCs exist (Figure 4 ). The first ''intermediate'' GRa BNC form is present on the way from the developing ''premature'' BNC to an ''activated'' BNC without showing signs of apoptosis (negative caspase-3 staining, Figure 1 (F 2 ) ). A second ''intermediate'' (þÀ) BNC form is present on the way from maturing from an ''activated'' to an ''inactivated'' GRa BNC, presenting signs of apoptosis (positive caspase 3, Figure 1 (F 0 ) ).
This study was not designed to investigate the underlying mechanisms regulating the formation of different BNC types. However, the proportion of BNC staining positively for GRa in 1 or 2 nuclei changed with advancing gestational age and we hypothesize that these changes are coincident with placental maturation early in gestation and with fetal hypothalamicpituitary-adrenal (HPA) maturation later in gestation. It has been demonstrated that BNCs develop from the fusion of 2 uninucleate trophoblast cells 22, 45, 46 and we may hypothesize that the different GRa-staining patterns indicate different maturational stages and function of a BNC. Although the regulatory factors that govern these processes are unknown and could not be investigated in this study, we hypothesize that cortisol itself may mediate these events and control of the production and migration of BNCs may play a pivotal role in ruminant implantation and placental growth. Early in gestation (50-100 dG), the mean number of (þþ) GRa BNCs increased and the number of (þÀ) and (ÀÀ) GRa BNCs did not change. Later in gestation (100-140 dG), as the fetal HPA axis matures and begins to secrete higher concentrations of cortisol, we observed a decrease in the mean numbers of (þþ) BNC resulting in an increased proportion of (þÀ) and (ÀÀ) GRa BNCs. Therefore, early in pregnancy, ''premature'' (ÀÀ) GRa BNC may develop directly to ''activated'' (þþ) GRa BNCs, since the number of ''intermediate'' (þÀ) GRa BNC did not change. Later in pregnancy with increased fetal cortisol due to HPA axis activation, ''premature'' (ÀÀ) GRa BNC may develop via the ''intermediate'' (þÀ) GRa BNC type to the ''active'' GRa BNC (þþ) which is represented by an increased number of ''intermediate'' (þÀ) GRa BNC (Figure 4 ).
Administration of DEX significantly decreased the number of (þþ) GRa BNCs at 100 and 140 dG compared to controls but simultaneously changed the composition of the BNC type resulting in a relative increase in the (þþ) compared to (þÀ) and (ÀÀ) GRa BNC types. By preventing the conversion from the (þþ) to the (þÀ) and (ÀÀ) GRa BNC form, the placenta may have compensated the loss of total GRa BNCs after DEX.
Conclusion
Three different BNC phenotypes were identified, and the activity of BNCs may be determined by the distribution of these 3 cell types. Early DEX increased the proportion of BNCs from a potentially ''inactive'' to an ''active'' form, and we hypothesize that this effect may act to increase the sensitivity of GRa BNCs in near term. Effects were sex-and cell type dependent suggesting a modified and sex-specific responsiveness of the placenta to endogenous cortisol. Our understanding on how endogenous GC and/or overexposure to exogenous GC can influence fetal and placental development begins with the GR. A thorough understanding of how maternal glucocorticoid administration influences placental cellular function will provide a better understanding about the role of the placenta in the fetal adaptive response.
